Salutaris Medical Devices™ Wet AMD Distance of Choroid Study Presented at ARVO 2016
Seattle, USA (May 4, 2016) – Today results from the Salutaris Medical Devices, Inc. (SalutarisMD®) wet age-related Macular Degeneration (wet AMD) Distance of Choroid Study (DOCS) were featured in two presentations at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) Annual Meeting.
The first poster, by Dr. Kamaljit Balaggan, presented clinical results informing an upcoming interventional study employing the SalutarisMD® novel episcleral brachytherapy device for treatment of wet AMD. Dr. Balaggan is a Consultant Vitreoretinal Surgeon and Medical Retina Consultant at Wolverhampton & Midland Counties Eye Infirmary and former medical and surgical retina fellow at Moorfields Eye Hospital, NIHR Biomedical Research CentreDr. Balaggan is a Consultant ophthalmic surgeon at Moorfields Eye Hospital, NIHR Biomedical Research Centre, and Consultant Ophthalmic Surgeron at Wolverhampton & Midland Counties Eye Infirmary.
Dr. Balaggan’s presentation evaluated variations in expected dwell times and doses to determine if a mean target depth is appropriate for patients receiving episcleral brachytherapy for treating wet AMD. Therapy dwell times were computed based on spectral-domain Optical Coherence Tomography (SD-OCT; Spectralis™, Heidelberg Engineering Inc.), swept-source OCT (SS-OCT; DRI-OCT-1 Atlantis™, TopCon Inc.), and ocular ultrasound imaging. Dr. Balaggan concluded, “Each patient should have individualized imaging studies to determine the target depth.”
A second poster presented an analysis of a sub-set of DOCS data by Dr. Daren Hanumuenthadu, Honorary Research Fellow at Moorfields Eye Hospital. Dr. Hanumuenthadu’s presentation utilized data acquired through a SalutarisMD® ™ sponsored study and described the repeatability of choroidal thickness measurements in wet AMD using the SS-OCT device. Studies have reported variation in OCT-derived choroidal thickness measurements in wet AMD patients being treated with anti-angiogenic agents. An understanding of its repeatability is required to define true clinical change rather than measurement variability alone. This study suggests that variation of more than 57μm in choroidal thickness is necessary to suggest clinical variation due to disease activity.
“We are excited that this work both informs our upcoming clinical studies and contributes to the understanding of this debilitating disease,” remarked Dr. Laurence Marsteller, SalutarisMD® CEO.
(Caution: Investigational Device. Limited by Federal Law to Investigational Use in the United States.)
SalutarisMD® (Salutaris Medical Devices, Inc. and Salutaris Medical Devices, Ltd.) is a pre-revenue medical device company developing an investigational ophthalmic treatment for Wet Age-related Macular Degeneration (Wet AMD). The SalutarisMD® patented technology incorporates a minimally invasive single-use brachytherapy procedure that can be performed in an outpatient setting in approximately 15 minutes. The patented and patent pending technology delivers a single-use brachytherapy procedure. SalutarisMD’s technology is being engineered to deliver improved outcomes for Wet AMD. For more information visit www.SalutarisMD.com or www.SalutarisMD.co.uk.
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. For more information visit www.arvo.org.
Salutaris Medical Devices, Inc.
4340 N. Campbell Ave.
Tucson, AZ 85718
Salutaris Medical Devices, Ltd.
Level 1, Bessemer Building
Imperial College London SW72AZ
+44 (0) 203 282 7166
Joanne Vitali, US Communications Director
Amanda Thomas, UK Communications Director
+44 (0) 1582 623660/
+44 (0) 7746 708500 mobile